Literature DB >> 34150144

Application value of UPLC-MS/MS in detecting serum concentration of anti-schizophrenic drugs in patients with mental illnes.

Shaochang Wu1, Guidong Zhu2, Dajin Zhou3, Hongtao Xu4, Longyou Zhao3.   

Abstract

OBJECTIVE: This study was designed to demonstrate the accuracy of ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) in detecting serum concentration of anti-schizophrenic drugs in patients with mental illness.
METHODS: The study participants were 186 schizophrenia patients treated in our hospital. Serum concentrations of anti-schizophrenic drugs in Chinese patients with mental illness were evaluated according to the reference intervals of drug therapy recommended in the guidelines.
RESULTS: Five drugs, namely Aripiprazole (ARI), Amisulpride (AMI), Olanzapine (OLA), Paliperidone (PAL) and Ziprasidone (ZIP) all showed good linearity within the linear range. The within-day precision of the above five drugs was all between 1.3%-8.9% and the inter-day precision was between 1.8%-7.6%, with within-day and inter-day relative standard deviations (RSDs) less than 15.00% and accuracy ranging from 87.00% to 106.73%. However, AMI had a mean blood concentration of 436.31±241.05 ng/mL (median concentration: 379.34 ng/mL), which was significantly higher than the reference range (100-320 ng/mL) recommended in the guidelines. Good recovery rates (86.21%-99.77%) were obtained after the samples were stored at room temperature for 24 h, at 4°C for 48h and at -20°C for half a year.
CONCLUSIONS: Given that UPLC-MS/MS renders more accurate results in detecting the concentration of psychotropic drugs, it can be applied clinically to detect the concentration of therapeutic drugs in patients with mental illness. AJTR
Copyright © 2021.

Entities:  

Keywords:  Ultra-high performance liquid chromatography-tandem mass spectrometry; drug concentration; schizophrenia

Year:  2021        PMID: 34150144      PMCID: PMC8205737     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  7 in total

1.  Translation and cross-cultural adaptation of outcome measurements for schizophrenia. EPSILON Study 2. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs.

Authors:  H C Knudsen; J L Vázquez-Barquero; B Welcher; L Gaite; T Becker; D Chisholm; M Ruggeri; A H Schene; G Thornicroft
Journal:  Br J Psychiatry Suppl       Date:  2000

2.  Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study.

Authors:  Xuemei Liu; Rui Chen; Guanghuai Zeng; Ying Gao; Xiuping Liu; Donglei Zhang; Pei Hu; Hongyun Wang; Ji Jiang
Journal:  Bioanalysis       Date:  2018-06-04       Impact factor: 2.681

3.  Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective.

Authors:  Jeffrey A Lieberman
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  A sensitive UPLC-MS/MS method for simultaneous determination of polyphenols and theaflavins in rat plasma: Application to a pharmacokinetic study of Da Hong Pao tea.

Authors:  Lin Wang; Ting Yan; Kexia Zhang; Feifeng Li; Jingming Jia; Gaosheng Hu
Journal:  Biomed Chromatogr       Date:  2019-02-04       Impact factor: 1.902

5.  Dysfunction of Large-Scale Brain Networks in Schizophrenia: A Meta-analysis of Resting-State Functional Connectivity.

Authors:  Debo Dong; Yulin Wang; Xuebin Chang; Cheng Luo; Dezhong Yao
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

6.  An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients.

Authors:  Cheng Cui; Pei Hu; Ji Jiang; Fansheng Kong; Hong Luo; Qian Zhao
Journal:  J Pharm Biomed Anal       Date:  2018-01-31       Impact factor: 3.935

7.  Simultaneous determination of trimethylamine N-oxide, choline, betaine by UPLC-MS/MS in human plasma: An application in acute stroke patients.

Authors:  Weibang Yu; Chuncao Xu; Guomin Li; Weipeng Hong; Ziyi Zhou; Canxing Xiao; Yuanqi Zhao; Yefeng Cai; Min Huang; Jing Jin
Journal:  J Pharm Biomed Anal       Date:  2018-02-03       Impact factor: 3.935

  7 in total
  1 in total

1.  Plasma metabolomics of schizophrenia with cognitive impairment: A pilot study.

Authors:  Yihe Jiang; Xiujia Sun; Miaowen Hu; Lei Zhang; Nan Zhao; Yifeng Shen; Shunying Yu; Jingjing Huang; Huafang Li; Wenjuan Yu
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.